DDInter556 DDInter905
Dihydrocodeine is an opioid analgesic used as an alternative or adjunct to codeine to treat moderate to severe pain, severe dyspnea, and cough. It is semi-synthetic, and was developed in Germany in 1908 during an international search to find a more effective antitussive agent to help reduce the spread of airborne infectious diseases such as tuburculosis. It was marketed in 1911.
Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. In contrast to the other class IA PI3Ks p110α and p110β, p110δ is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils. By inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and type 4 signalling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib has been shown to result in inhibition of chemotaxis and adhesion, and reduced cell viability.
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Galantamine
Galantamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Oxycodone
Oxycodone {u} may lead to a major life threatening interaction when taken with {v} Idelalisib
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Galantamine
Galantamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cabozantinib
Cabozantinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Oxymorphone
Oxymorphone {u} (Compound) resembles {v} (Compound) Oxycodone
Oxycodone {u} may lead to a major life threatening interaction when taken with {v} Idelalisib
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Oxycodone
Oxycodone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sibutramine
Sibutramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Idelalisib
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Hydrocodone
Hydrocodone {u} (Compound) resembles {v} (Compound) Naltrexone
Naltrexone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Oxymorphone
Oxymorphone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sibutramine
Sibutramine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Idelalisib
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Oxycodone
Oxycodone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alefacept
Alefacept {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Galantamine
Galantamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Oxaliplatin
Oxaliplatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Dihydrocodeine {u} (Compound) resembles {v} (Compound) Dextromethorphan
Dextromethorphan {u} may cause a minor interaction that can limit clinical effects when taken with {v} Valdecoxib
Valdecoxib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Idelalisib
Dihydrocodeine (Compound) resembles Galantamine (Compound) and Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Dihydrocodeine (Compound) resembles Oxycodone (Compound) and Oxycodone may lead to a major life threatening interaction when taken with Idelalisib
Dihydrocodeine (Compound) resembles Galantamine (Compound) and Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Dihydrocodeine (Compound) resembles Oxymorphone (Compound) and Oxymorphone (Compound) resembles Oxycodone (Compound) and Oxycodone may lead to a major life threatening interaction when taken with Idelalisib
Dihydrocodeine (Compound) resembles Oxycodone (Compound) and Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Dihydrocodeine (Compound) resembles Hydrocodone (Compound) and Hydrocodone (Compound) resembles Naltrexone (Compound) and Naltrexone may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Dihydrocodeine (Compound) resembles Oxymorphone (Compound) and Oxymorphone may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Dihydrocodeine (Compound) resembles Oxycodone (Compound) and Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Dihydrocodeine (Compound) resembles Galantamine (Compound) and Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Dihydrocodeine (Compound) resembles Dextromethorphan (Compound) and Dextromethorphan may cause a minor interaction that can limit clinical effects when taken with Valdecoxib and Valdecoxib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib